The Effect of a Self-Retaining Pannus Retractor in Obese Patients Undergoing Cesarean Section

Overview

The purpose of this study is to investigate the effects of the Traxi Pannus retractor in obese patients (BMI ≥30 kg/m2) who undergo Cesarean sections compared to routine pannus retraction techniques. Patients will be randomized to the use of the Traxi retractor during Cesarean section (treatment group) or the use of traditional pannus retraction techniques (control group). The primary outcome to be followed is surgical site disruption. The investigators will also assess the duration of surgery or length of time from skin incision to delivery of the infant, change in hemoglobin, estimated blood loss, postoperative length of stay, need for hospital readmission or emergency room visits, or other complication rates between the two groups.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2, 2017

Detailed Description

Surgical site infections (SSI) are an important cause of morbidity following cesarean sections. The rate of surgical site infections following cesarean section in the United States is estimated between 3-15%, depending on the population studied, definitions of surgical site infection used, and length of time studied and is often underestimated. Morbidities include longer length of hospital stay, hospital readmission, wound opening and re-exploration, need for home health care, increased health care costs and loss of productivity. The risk of developing a SSI after a Cesarean section is increased with certain patient characteristics, such as obesity and duration of surgery and is decreased with the use prophylactic antibiotics prior to the skin incision.

Obesity is a significant public health problem and the incidence continues to increase in the United States. It has been shown to be associated with increased risk of SSI after cesarean section in several studies. Olsen et al reviewed 1,605 patients who underwent cesarean section and found increased BMI at admission was an independent risk factor for SSI. In another study of 19,416 women in Israel who had cesarean deliveries, women who had a BMI ≥30 kg/m2 had an increased risk for infection (odds ratio [OR} =2.2; 95% Confidence Interval [CI]. Leth, et al. also found obesity as a risk factor associated with wound infection. In this study of 2,492 consecutive women who had cesarean sections in Denmark, infection rates increased with increasing BMI, with women with a BMI kg/m2 30.0-34.9 having an infection rate of 19.1% and women with a BMI of 35.0-39.9 kg/m2 and of ≥40 kg/m2 both having infection rates of 31.1%. Hypotheses for the increased rate of wound infections in obese patients include decreased vascularity of adipose tissue, increase in wound area, and poorer penetration of prophylactic antibiotics to adipose tissue. Adequate surgical exposure and good visualization are paramount in abdominal surgery. Retraction of the pannus cephalad is often required for adequate visualization and access to the lower abdomen and thus the lower uterine segment. Several studies have been shown that pfannensteil or joel-cohen incisions are superior to vertical incisions due to increased risk of classical cesarean delivery in the case of the obese gravida. Limited studies have been completed to assess supra umbilical incisions.

Other methods of pannus retraction are currently utilized in obstetrics surgery, mostly with surgical tape or Montgomery straps. However, there are currently no clinical trials comparing types of pannus retractors. Potential benefits from the Traxi retractor are decreased operating time, decreased need for additional operating room personnel, and increased ease of delivery of neonate. In addition, the Traxi is designed to stay on for 24 hours in order to elevate the pannus, this will decrease exposure to moisture and possibly other bacteria as the skin begins to heal.

Interventions

  • Device: Traxi Pannus Retractor
    • traxi® Panniculus Retractor is a retraction device used for retraction of the panniculus during surgical procedures. traxi retracts and holds the panniculus for the duration of the operation, freeing the surgeons hands and those of the staff to better care for the patient.

Arms, Groups and Cohorts

  • Active Comparator: Treatment
    • Subjects will receive use of the Traxi pannus retractor when undergoing cesarean section
  • No Intervention: Standard
    • Patients will receive use of the standard of care option which is the montgomery straps

Clinical Trial Outcome Measures

Primary Measures

  • Wound Disruption Rates
    • Time Frame: 24 hours from placement of device
    • To determine if there is a difference in wound disruption rates, in obese patients who have Cesarean sections when the Traxi retractor is used during Cesarean sections, when compared to traditional pannus retractor techniques, montogmery straps.

Secondary Measures

  • Duration of Surgery or Length of Time From Skin Incision to Delivery of the Infant
    • Time Frame: At time of surgery
    • To determine if there is a difference in duration of surgery or length of time from skin incision to delivery of the infant between the treatment group and the control/standard group.
  • Change in Hemoglobin
    • Time Frame: 24 hours after surgery
    • To determine if there is a difference in change in hemoglobin between the control/standard group and the treatment group.
  • Estimated Blood Loss
    • Time Frame: At time of surgery
    • To determine if there is a difference in estimated blood loss between the treatment group and the control/standard group.
  • Postoperative Length of Stay
    • Time Frame: 3-4 days
    • To determine if there is a difference in postoperative length of stay between the treatment group and the control/standard group.
  • Other Complication Rate
    • Time Frame: 6 weeks
    • To determine if there is a difference in other complication rates between the treatment group and the control/standard group.
  • Need for Hospital Readmission or Emergency Room Visits
    • Time Frame: 6 weeks
    • To determine if there is a difference in need for hospital readmission or emergency room visits between the treatment group and the control/standard group.

Participating in This Clinical Trial

Inclusion Criteria

  • Pregnant women with a BMI greater than or equal to 30 kg/m squared, aged 14-50 years old, undergoing non-emergent cesarean section for delivery and require pannus displacement for surgery.

Physicians Inclusion would include any physician who routinely perform C-sections

Exclusion Criteria

  • Patients undergoing emergency Cesarean-section Pre-existing concurrent infection including chorioamnionitis State of immunosuppression (ie. HIV, cancer) Long-term steroid use (>2 days) Patients with a BMI <30 kg/m2, or those with a BMI >/=30kg who do not require pannus retraction.

If there is a rash in the area of retraction Adhesive/tape allergy. Physicians exclusion would include any physician who does not routinely perform C-sections.

Gender Eligibility: Female

Minimum Age: 14 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • St. Louis University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jennifer Goldkamp, MD, MD – St. Louis University
  • Overall Official(s)
    • Jennifer Goldkamp, MD, Principal Investigator, St. Louis University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.